

# PreveCeutical Medical Inc.

10:31 19 Dec 2018

## PreveCeutical says C\$16.25M Crushedit supply deal and Asterion Cannabis licensing deal among 2018 milestones

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said Wednesday that a letter of intent with Crushedit LLC regarding a C\$16.25 million cannabidiol isolate supply agreement and a natural-health- product licensing deal with Asterion Cannabis Inc are among the milestones achieved in 2018.

Vancouver-based PreveCeutical said in a press release that its other accomplishments include the start of a medicinal cannabis division, completion of a C\$6.5 million financing and expansion of its Australian operations.

**READ:** PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

The company added that it has reached its 2018 research targets for its scorpion venom-derived peptide program and its soluble gel drug delivery platform program. PreveCeutical also said it completed a workshop in Australia to advance its dual gene therapy research and development program.

Shares of PreveCeutical fetched C\$0.05 in Wednesday's Canadian trading and US\$0.04 on the OTC Markets.

In November, the company announced that it had entered into a letter of intent with Nevada-registered Crushedit, under which PreveCeutical's cannabis division would supply Crushedit with at least 2,500 kilograms of CBD isolate over 12 months at C\$6,500 per kilogram, for a total of at least C\$16.25 million.

PreveCeutical added Wednesday that its letter of intent with the Penta 5 Group has expired. PreveCeutical said complexities regarding the structure of the group made a proposed share purchase transaction unfeasible. The companies are in negotiations regarding possible alternative transaction structures, according to PreveCeutical.

In August, Asterion granted PreveCeutical a worldwide license to use, manufacture, distribute and sell three Health Canada-approved natural-health products.


Last month, the company said it had developed a way to convert phytocannabinoids extracted from the company's five cannabis strains from acid to neutral.

Contact Dennis Fitzgerald at [dennis@proactiveinvestors.com](mailto:dennis@proactiveinvestors.com)

**Price:** 0.015

**Market Cap:** \$5.95 m

### 1 Year Share Price Graph



April 2019 September 2019 March 2020

### Share Information

**Code:** PREV

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>0.075</b>	<b>0.01</b>

**Sector:** **Medical technology & services**

**Website:** [preveceutical.com](http://preveceutical.com)

### Company Synopsis:

*PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).